valproic acid and vorinostat

valproic acid has been researched along with vorinostat in 99 studies

Research

Studies (99)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	27 (27.27)	29.6817
2010's	65 (65.66)	24.3611
2020's	7 (7.07)	2.80

Authors

Authors	Studies
Burnett, R; Gottesfeld, JM; Herman, D; Jenssen, K; Perlman, SL; Soragni, E	1
Lombardo, F; Obach, RS; Waters, NJ	1
Bora-Tatar, G; Dalkara, S; Dayangaç-Erden, D; Demir, AS; Erdem-Yurter, H; Yelekçi, K	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Corey, DR; Sakurai, F; Yu, D	1
Madsen, AS; Olsen, CA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Forgione, M; Hailu, GS; Mai, A; Robaa, D; Rotili, D; Sippl, W	1
Brindisi, M; Brogi, S; Butini, S; Campiani, G; Gemma, S; Saraswati, AP	1
Abd El-Hafeez, AA; Abdelhamid, D; Abuo-Rahma, GEA; Ghosh, P; Hayallah, AM; Katkar, GD; Mostafa, YA; Mustafa, M	1
Qiu, X; Tan, Y; Wan, L; Wang, H; Yang, L; Yang, Z; Zhu, L	1
Alfano, AI; Barone, S; Brindisi, M; Cassese, E; Summa, V	1
Desmond, JC; Gui, D; Koeffler, HP; Kumagai, T; Miyakawa, I; Said, JW; Takai, N; Whittaker, S	1
Ballarini, M; Facchetti, F; La Porta, CA; Minucci, S; Perego, P; Previdi, S	1
Kawamata, N; Koeffler, HP; Kumagai, T; Said, JW; Saitoh, T; Sakajiri, S	1
Avila, AM; Fischbeck, KH; Huynh, TN; Kernochan, LE; Russo, ML; Sumner, CJ; Woodling, NS	1
Kupisz, K; Polberg, K; Stepulak, A; Stryjecka-Zimmer, M	1
Bradbury, CA; Bunce, CM; Craddock, C; Drayson, MT; Hayden, R; Khanim, FL; Turner, BM; White, DA	1
Batra, A; Dinarello, CA; Fantuzzi, G; Fedke, I; Glauben, R; Lehr, HA; Leoni, F; Mascagni, P; Siegmund, B; Zeitz, M	1
Bueso-Ramos, C; Garcia-Manero, G; Hoshino, K; Quintas-Cardama, A; Richon, VM; Sanchez-Gonzalez, B; Yang, H	1
Guo, B; Huang, X	1
Mack, GS	1
Cinatl, J; Doerr, HW; Kreuter, J; Michaelis, M; Ogbomo, H	1
Gronemeyer, H; Herbrecht, R; Lieb, M; Lutz, P; Manzo, F; Shankaranarayanan, P; Tsapis, M	1
Alam, HB; Chen, H; Kirkpatrick, J; Koustova, E; Li, Y; Lin, T; Liu, B; Rhee, P; Sailhamer, EA; Shults, C	1
Cassell, M; Lindsay, DS; Mitchell, SM; Reilly, CM; Strobl, JS	1
Dedes, KJ; Fedier, A; Fink, D; Imesch, P; Von Bueren, AO	1
Mahlknecht, U; Schönbein, C	1
Carducci, MA; Galloway, N; Kachhap, S; Kortenhorst, MS; Parmigiani, G; Shabbeer, S; Verheul, HM; Zahurak, M	1
Echigo, S; Endo, M; Rikiishi, H; Shinohara, F; Suzuki, M	1
Batty, N; Issa, JP; Malouf, GG	1
Duque-Afonso, J; Hauswald, S; Keller, U; Licht, T; Lübbert, M; Peschel, C; Schertl, FM; Wagner, MM	1
Caby, S; Capron, M; Cosseau, C; Dissous, C; Dubois, F; Grunau, C; Oger, F; Pierce, RJ	1
Debatin, KM; Dittrich, A; Fulda, S; Häcker, S; Krauss, J; Mohr, A; Rutkowski, S; Schweitzer, T	1
Dedes, KJ; Fedier, A; Fink, D; Furlato, M; Imesch, P	1
Scott, BL	1
Chiang, AK; Hui, KF	1
Fricke, A; Mahlknecht, U; Ong, MF; Purrucker, JC; Rübe, C; Rübe, CE	1
Chung, J; Kim, A; Kim, YS; Kwon, MH; Park, JS; Sung, ES	1
Becker, K; Göttlicher, M; Hapfelmeier, A; Höfler, H; Keller, G; Langer, R; Luber, B; Mutze, K; Novotny, A; Ott, K	1
Bischof, M; Blattmann, C; Debus, J; Deubzer, HE; Ehemann, V; Huber, PE; Kulozik, AE; Oertel, S; Thiemann, M; Weber, KJ; Witt, O	1
Kidd, SK; Schneider, JS	1
Li, C; Mizutani, E; Ono, T; Terashita, Y; Wakayama, T; Yamagata, K	1
Elknerova, K; Lacinova, Z; Marinov, I; Myslivcova, D; Stöckbauer, P; Uherkova, L	1
Biçaku, E; Marchion, DC; Münster, PN; Thomas, S; Thurn, KT	1
Blanquart, C; Boutin, B; Fonteneau, JF; Grégoire, M; Gueugnon, F; Guillot, F; Leclercq, S; Padieu, M; Pouliquen, D; Rogel, A	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Almasan, A; Bodo, J; Hsi, ED; Maciejewski, JP; Sedlak, J	1
Abe, W; Kawano, Y; Li, H; Narahara, H; Nasu, K; Takai, N; Tsuno, A	1
Agapova, OA; Bowcock, AM; Harbour, JW; Kneass, ZT; Landreville, S; Lee, RS; Matatall, KA; Onken, MD	1
Bild, AH; Cheng, L; Cohen, AL; Moos, PJ; Soldi, R; Sun, Y	1
Gray, SG	1
Addis, M; Bailey, K; Chanda, S; de Araujo Furtado, M; Lumley, LA; Moffett, M; Pak, T; Robertson, BD; Rossetti, F; Shields, M; Yourick, DL	1
Gupta, V; Halsall, J; Nightingale, KP; O'Neill, LP; Turner, BM	1
Chen, CN; Cotroneo, E; Hajji, N; Li, M; McKinsey, TA; Oliver, E; Stenmark, KR; Wang, D; Wharton, J; Wilkins, MR; Zhao, L	1
Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C	1
Barbetti, V; Cheloni, G; Dello Sbarba, P; Fabiani, E; Gozzini, A; Marzi, I; Rovida, E; Santini, V	1
Ali, MF; Chachadi, VB; Cheng, PW	1
Correia, AO; da Graça Naffah-Mazzacorati, M; de Castro Brito, GA; de Oliveira Gonçalves, D; Félix, FH; Leal, LK; Neves, KR; Santos Cerqueira, G; Siqueira, RM; Viana, GS; Ximenes, JC	1
Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C	1
Celano, M; D'Agostino, M; Damante, G; Filetti, S; Maggisano, V; Micali, S; Navarra, M; Puppin, C; Russo, D; Sponziello, M	1
Aiyetan, PO; Carducci, MA; Gupta, A; Jans, JJ; Kachhap, SK; Kortenhorst, MS; Marchionni, L; Rodríguez, R; Van der Groep, P; van der Wall, E; Van Diest, PJ; Verheul, HM; Wissing, MD	1
Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD	1
Bøe, SO; Engedal, N; Hokland, P; Simonsen, A; Torgersen, ML	1
Araki, K; Matsushita, Y; Mukae, T; Omotuyi, Oi; Ueda, H	1
Cadeiras, M; Deng, M; Fang, C; Kim, AK; Liem, DA; Lu, H; Ping, P; Scruggs, SB; Wang, D; Yang, P; Yu, H; Zong, NC	1
Cassidy, MR; Gainsbury, ML; Heydrick, S; Sheldon, HK; Sherburne, AC; Stucchi, AF	1
Beck, JF; Becker, S; Krämer, OH; Marx, C; Palani, CD; Sonnemann, J; Wittig, S	1
Booth, L; Conley, A; Cruickshanks, N; Dent, P; Grant, S; Poklepovic, A; Ridder, T; Roberts, JL	1
Cassidy, AW; Foley, AG; Regan, CM	1
Bezecny, P	1
Goldstein, S; Krishna, MC; Mitchell, JB; Samuni, Y; Wink, DA	1
Kouraklis, G; Nebiker, CA; Tampaki, EC; Tampakis, A	1
Blasco-Angulo, N; Comella, JX; Cornago, M; Garcia-Alberich, C; Herreros, J; Llovera, M; Nager, M; Sanchis, D; Vall-Llaura, N	1
Ayllon, V; Bueno, C; Cobo, M; Guerrero-Carreno, X; Lamolda, M; Martin, F; Menendez, P; Navarro-Montero, O; Ramos-Mejia, V; Real, PJ; Romero, T; Toscano, MG	1
Mukherjee, S; Ornstein, MC; Sekeres, MA	1
Khanna, KK; Lim, YC; Ward, A; Wiegmans, AP; Yap, PY	1
Dmoszynska-Graniczka, M; Grabarska, A; Gumbarewicz, E; Luszczki, JJ; Polberg, K; Stepulak, A; Wawruszak, A	1
Cheng, Z; Hao, Y; Liu, H; Liu, N; Liu, X; Peng, X; Qi, W; Sun, Z; Wang, F; Wu, Q; Xu, L; Yan, J; Zheng, N; Zhu, J; Zhu, X	1
Aurisicchio, L; Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Marra, E; Moccia, T; Noto, A; Roca, MS; Roscilli, G; Vitagliano, C	1
Glasow, A; Kortmann, RD; Menzel, F; Patties, I	1
Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M	1
Bug, G; Romanski, A	1
Figg, WD; Goey, AK; Peer, CJ; Sissung, TM	1
Hayakawa, T; Katagiri, C; Kondo, T; Matsushita, M; Nakamura, W; Nakamura-Higa, M; Shimizu-Okabe, C; Takamatsu, G; Takayama, C; Tomoyuki, T; Wakabayashi, S	1
Gumbarewicz, E; Guz, M; Jarząb, A; Polberg, K; Stepulak, A; Łuszczki, JJ	1
Cui, KQ; Huang, B; Li, ZP; Liu, QY; Lu, XR; Shi, DS; Sun, JM; Xu, ZF	1
Bahna, SG; Niles, LP	1
Fujii, K; Idogawa, M; Iwatsuki, K; Jimura, N; Kanekura, T; Kondo, T; Suzuki, N	1
Maeurer, M; Rao, M; Valentini, D; Zumla, A	1
Bensaid, D; Bertrand, P; Blanquart, C; Blondy, T; Dehame, V; Deshayes, S; Errami, M; Grégoire, M	1
Kavoosi, F; Mansoori, O; Sanaei, M	1
Iizuka, N; Ishii, K; Kawano, C; Kuroyama, M; Mori, A; Morita, A; Nakahara, T; Sakamoto, K	1
Fan, L; Jiang, T; Qiu, X; Yin, Y; Zhu, Q	1
Belmonte-Reche, E; Corpas-López, V; de Pedro, N; Díaz-Gavilán, M; Franco-Montalbán, F; Gómez-Vidal, JA; López-Viota, J; López-Viota, M; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Márquez, F; Pérez-Del Palacio, J	1
Lu, Y; Qiu, X; Rong, X; Yang, J	1
Bergmann, M; Egger, G; Homola, J; Hunter, L; Kabiljo, J; Laengle, J; Prodinger, S	1
Al-Hasani, K; El-Osta, A; K N, H; Khurana, I; Lunke, S; Maxwell, S; Okabe, J	1
Aoshima, K; Kimura, T; Kobayashi, A; Suzuki, T; Yamazaki, J	1

Reviews

12 review(s) available for valproic acid and vorinostat

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. Journal of medicinal chemistry, 2017, 06-22, Volume: 60, Issue:12 Topics: Animals; Antiparasitic Agents; Drug Repositioning; Helminth Proteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leishmania; Plasmodium; Protozoan Proteins; Schistosoma; Toxoplasma; Trypanosoma	2017
From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. Bioorganic & medicinal chemistry, 2021, 12-15, Volume: 52 Topics: Biological Products; Drug Design; Drug Discovery; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Structure	2021
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology. Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4 Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Histone Deacetylase 6; Humans; Signal Transduction	2022
[Histone deacetylase inhibitors as a new generation of anti-cancer agents]. Postepy higieny i medycyny doswiadczalnej (Online), 2005, Mar-11, Volume: 59 Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Phenylbutyrates; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2005
Histone deacetylase inhibitors as anti-neoplastic agents. Cancer letters, 2009, Aug-08, Volume: 280, Issue:2 Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatin; Clinical Trials as Topic; Depsipeptides; DNA Methylation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2009
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Epigenetic treatment of neurological disease. Epigenomics, 2011, Volume: 3, Issue:4 Topics: Alzheimer Disease; Butylamines; Cell Differentiation; Endoplasmic Reticulum Stress; Epigenesis, Genetic; Histone Code; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Huntington Disease; Hydroxamic Acids; Neurons; Phenylbutyrates; Protein Processing, Post-Translational; Resveratrol; Stilbenes; Valproic Acid; Vorinostat	2011
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:6 Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Depsipeptides; Epigenesis, Genetic; Glioblastoma; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2014
Histone deacetylase inhibitors and colorectal cancer: what is new? Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:9 Topics: Antineoplastic Agents; Azacitidine; Colorectal Neoplasms; Combined Modality Therapy; Decitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2014
More is better: combination therapies for myelodysplastic syndromes. Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat	2015
Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics, 2016, Volume: 17, Issue:16 Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Pharmacogenetics; Sulfonamides; Valproic Acid; Vorinostat	2016

Other Studies

87 other study(ies) available for valproic acid and vorinostat

Article	Year
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nature chemical biology, 2006, Volume: 2, Issue:10 Topics: Acetylation; Alleles; Anilides; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Frataxin; Friedreich Ataxia; Gene Expression Regulation; Gene Silencing; HeLa Cells; Heterochromatin; Histone Deacetylase Inhibitors; Histones; Humans; Iron-Binding Proteins; Molecular Structure; RNA, Messenger; Transcription, Genetic	2006
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorganic & medicinal chemistry, 2009, Jul-15, Volume: 17, Issue:14 Topics: Caffeic Acids; Carboxylic Acids; Catalytic Domain; Chlorogenic Acid; Curcumin; Enzyme Inhibitors; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Models, Molecular; Molecular Structure; Protein Binding	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. Bioorganic & medicinal chemistry letters, 2011, Sep-15, Volume: 21, Issue:18 Topics: Clone Cells; Epigenesis, Genetic; Fibroblasts; Gene Expression Profiling; Humans; Methyl-CpG-Binding Protein 2; Molecular Structure; Mutation; Organic Chemicals; Polymerase Chain Reaction; Rett Syndrome; RNA, Messenger; Stereoisomerism	2011
Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme. Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11 Topics: Benzamides; Coumarins; Enzyme Assays; Fluorometry; Furans; Humans; Isoenzymes; Kinetics; Lysine; Naphthols; Protein Processing, Post-Translational; Quinolines; Recombinant Proteins; Sirtuins; Structure-Activity Relationship; Substrate Specificity; Succinates; Suramin	2012
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of medicinal chemistry, 2020, 01-09, Volume: 63, Issue:1 Topics: Animals; Biomarkers; Cell Line; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Mice; Protein Processing, Post-Translational; Rare Diseases	2020
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. European journal of medicinal chemistry, 2021, Oct-15, Volume: 222 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Focal Adhesion Kinase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured	2021
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-01, Volume: 10, Issue:3 Topics: Agar; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cadherins; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Chromatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dose-Response Relationship, Drug; Endometrial Neoplasms; Enzyme Inhibitors; Female; Flow Cytometry; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; In Situ Nick-End Labeling; Mice; Mice, Nude; Precipitin Tests; Proto-Oncogene Proteins c-bcl-2; S Phase; Sodium Oxybate; Time Factors; Tumor Suppressor Proteins; Valproic Acid; Vorinostat	2004
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis : an international journal on programmed cell death, 2004, Volume: 9, Issue:5 Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Melanoma; Membrane Glycoproteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat	2004
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Experimental hematology, 2005, Volume: 33, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia; Lymphocytes; Lymphoma; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Treatment Outcome; Valproic Acid; Vorinostat	2005
The role of histone acetylation in SMN gene expression. Human molecular genetics, 2005, May-01, Volume: 14, Issue:9 Topics: Acetylation; Animals; Cells, Cultured; Chromatin Immunoprecipitation; Cyclic AMP Response Element-Binding Protein; Enzyme Inhibitors; Epigenesis, Genetic; Fibroblasts; Gene Dosage; Gene Expression; Gene Expression Regulation, Developmental; Histone Deacetylase Inhibitors; Histones; Humans; Hybridomas; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Muscular Atrophy, Spinal; Nerve Tissue Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA-Binding Proteins; SMN Complex Proteins; Survival of Motor Neuron 2 Protein; Transcription, Genetic; Valproic Acid; Vorinostat	2005
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005, Volume: 19, Issue:10 Topics: Acetylation; Acute Disease; Adult; Antigens, CD34; Butyrates; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid; Myeloid Cells; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2005
Histone hyperacetylation is associated with amelioration of experimental colitis in mice. Journal of immunology (Baltimore, Md. : 1950), 2006, Apr-15, Volume: 176, Issue:8 Topics: Acetylation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; In Vitro Techniques; Mice; Mice, Inbred C57BL; Valproic Acid; Vorinostat	2006
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Idarubicin; Leukemia; Protein Processing, Post-Translational; RNA, Messenger; Valproic Acid; Vorinostat	2006
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer research, 2006, Sep-15, Volume: 66, Issue:18 Topics: Adenomatous Polyposis Coli Protein; Apoptosis; beta Catenin; Colonic Neoplasms; Down-Regulation; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; RNA, Small Interfering; Survivin; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Transfection; Valproic Acid; Vorinostat	2006
Epigenetic cancer therapy makes headway. Journal of the National Cancer Institute, 2006, Oct-18, Volume: 98, Issue:20 Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Methyltransferases; Neoplasms; Randomized Controlled Trials as Topic; Valproic Acid; Vorinostat	2006
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS letters, 2007, Apr-03, Volume: 581, Issue:7 Topics: Cell Line; Cytotoxicity, Immunologic; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; NF-kappa B; Receptors, Immunologic; Valproic Acid; Vorinostat	2007
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:7-8 Topics: Apoptosis; Benzamides; Burkitt Lymphoma; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Glucocorticoids; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2007
Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery, 2007, Volume: 141, Issue:6 Topics: Acetylation; Animals; Enzyme Inhibitors; Gene Expression; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Liver; Lung; Male; Rats; Rats, Sprague-Dawley; Resuscitation; Shock, Hemorrhagic; Valproic Acid; Vorinostat	2007
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. The Journal of parasitology, 2007, Volume: 93, Issue:3 Topics: Animals; Antiprotozoal Agents; Butyrates; Cattle; Cell Line; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxylamines; Inhibitory Concentration 50; Niacinamide; Parasitic Sensitivity Tests; Phenylbutyrates; Quinolines; Toxoplasma; Valproic Acid; Vitamin B Complex; Vorinostat	2007
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. International journal of oncology, 2007, Volume: 31, Issue:3 Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; DNA Mismatch Repair; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Inhibitors; Flow Cytometry; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2007
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica, 2008, Volume: 93, Issue:3 Topics: Acute Disease; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Screening Assays, Antitumor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Integrin alpha4beta1; Leukemia, Myeloid; Leukocytes, Mononuclear; Neoplasm Proteins; Neoplasm, Residual; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Valproic Acid; Vorinostat	2008
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Microarray Analysis; Prostatic Neoplasms; Valproic Acid; Vorinostat	2008
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6 Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 12; Caspase Inhibitors; Caspases, Initiator; Cell Line, Tumor; Cinnamates; Cisplatin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Inhibitors; Eukaryotic Initiation Factor-2; Female; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Situ Nick-End Labeling; Membrane Glycoproteins; Mouth Neoplasms; Phosphorylation; Protein Phosphatase 1; Proto-Oncogene Proteins c-akt; Thapsigargin; Thiourea; Tunicamycin; Valproic Acid; Vorinostat	2009
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Acute Disease; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Biological Transport; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Immunoblotting; K562 Cells; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; Pharmaceutical Preparations; Phenotype; Phenylbutyrates; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid; Vorinostat	2009
Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Molecular and biochemical parasitology, 2009, Volume: 168, Issue:1 Topics: Acetylation; Animals; Apoptosis; Caspase 3; Caspase 7; Chromatin Immunoprecipitation; DNA, Protozoan; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; In Situ Nick-End Labeling; Molecular Sequence Data; Schistosoma mansoni; Sequence Analysis, DNA; Survival Analysis; Up-Regulation; Valproic Acid; Vorinostat	2009
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene, 2009, Sep-03, Volume: 28, Issue:35 Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Silencing; Heterozygote; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon-gamma; Medulloblastoma; Neoplasms; Pyridines; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Valproic Acid; Vorinostat	2009
MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. International journal of oncology, 2009, Volume: 35, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoprecipitation; Valproic Acid; Vorinostat	2009
Clinical roundtable monograph. Combination therapies for MDS. Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:7 Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat	2009
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. International journal of cancer, 2010, May-15, Volume: 126, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Fluorescent Antibody Technique; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia; Polymerase Chain Reaction; Stomach Neoplasms; Valproic Acid; Vorinostat	2010
HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. Oncology reports, 2010, Volume: 23, Issue:1 Topics: Benzamides; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Radiation; Fibroblasts; Histone Deacetylases; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Pyridines; Signal Transduction; Sodium Oxybate; Time Factors; Valproic Acid; Vorinostat	2010
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis : an international journal on programmed cell death, 2010, Volume: 15, Issue:10 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Down-Regulation; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mitochondria; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Valproic Acid; Vorinostat	2010
Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Annals of surgical oncology, 2010, Volume: 17, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2010
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. International journal of radiation oncology, biology, physics, 2010, Sep-01, Volume: 78, Issue:1 Topics: Antigens, Nuclear; Apoptosis; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Binding Proteins; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ku Autoantigen; Osteosarcoma; Photons; Radiation Tolerance; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Tumor Stem Cell Assay; Valproic Acid; Vorinostat	2010
Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain research, 2010, Oct-01, Volume: 1354 Topics: 1-Methyl-4-phenylpyridinium; Acetylation; Analysis of Variance; Animals; Apoptosis; Butyric Acid; Cell Line; Cells, Cultured; Dopamine; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Nerve Degeneration; Neurons; Rats; Valproic Acid; Vorinostat	2010
Inhibition of class IIb histone deacetylase significantly improves cloning efficiency in mice. Biology of reproduction, 2010, Volume: 83, Issue:6 Topics: Animals; Apoptosis; Cell Line; Cellular Reprogramming; Cloning, Organism; Embryonic Development; Female; Fetal Development; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Hydroxamic Acids; Isoenzymes; Male; Mice; Mice, Transgenic; Nuclear Transfer Techniques; Oocytes; Pluripotent Stem Cells; Valproic Acid; Vorinostat	2010
Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence. Neoplasma, 2011, Volume: 58, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2011
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast cancer research and treatment, 2011, Volume: 130, Issue:2 Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Membrane Proteins; Microtubule-Associated Proteins; Panobinostat; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Signal Transduction; Tamoxifen; Valproic Acid; Vorinostat	2011
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. The European respiratory journal, 2011, Volume: 38, Issue:5 Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pleural Neoplasms; T-Lymphocytes, Cytotoxic; Valproic Acid; Vorinostat	2011
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis : an international journal on programmed cell death, 2011, Volume: 16, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma; Sulfides; Tumor Suppressor Protein p53; Valproic Acid; Vorinostat	2011
Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. Human reproduction (Oxford, England), 2011, Volume: 26, Issue:9 Topics: Acetylation; Adult; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Endometriosis; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Peptides, Cyclic; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Valproic Acid; Vorinostat	2011
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy, Adjuvant; Computer Simulation; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplasm Micrometastasis; Panobinostat; Tumor Burden; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Uveal Neoplasms; Valproic Acid; Vorinostat; Xenograft Model Antitumor Assays	2012
A genomic approach to predict synergistic combinations for breast cancer treatment. The pharmacogenomics journal, 2013, Volume: 13, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genomics; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MCF-7 Cells; Protein Kinase Inhibitors; Up-Regulation; Valproic Acid; Vorinostat	2013
Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. Neurotoxicology, 2012, Volume: 33, Issue:3 Topics: Animals; Anticonvulsants; Brain; Brain Mapping; Brain Waves; Chemical Warfare Agents; Cytoprotection; Diazepam; Drug Therapy, Combination; Electroencephalography; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Seizures; Soman; Time Factors; Valproic Acid; Vorinostat	2012
Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PloS one, 2012, Volume: 7, Issue:3 Topics: Acetylation; Blotting, Western; Cell Cycle; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Valproic Acid; Vorinostat	2012
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation, 2012, Jul-24, Volume: 126, Issue:4 Topics: Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Hypertension, Pulmonary; Hypoxia; Lung; Male; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Valproic Acid; Vorinostat	2012
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer research, 2012, Volume: 32, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat	2012
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 2013, Volume: 8, Issue:2 Topics: Acetylation; Apoptosis; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Lysine; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Time Factors; Transcription Factors; Valproic Acid; Vorinostat	2013
Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a. PloS one, 2013, Volume: 8, Issue:2 Topics: CA-19-9 Antigen; Cell Line; Glycoproteins; Glycosyltransferases; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Mucin-1; Oligosaccharides; Prostate; Prostatic Neoplasms; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2013
Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn-Schmiedeberg's archives of pharmacology, 2013, Volume: 386, Issue:7 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anticonvulsants; Butyric Acid; Carrageenan; Drug Synergism; Edema; Foot; Formaldehyde; Hot Temperature; Hydroxamic Acids; Leukocyte Count; Male; Mice; Pain; Pentoxifylline; Peritonitis; Peroxidase; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat	2013
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:7 Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon-gamma; Melanoma; Neoplasms; RNA, Messenger; Telomerase; Telomere; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat	2013
Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. Endocrine, 2014, Volume: 45, Issue:1 Topics: Animals; Cell Line, Tumor; Cells, Cultured; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression; Histone Deacetylase Inhibitors; Hydroxamic Acids; Leydig Cell Tumor; Male; Rats; Symporters; Testicular Neoplasms; Valproic Acid; Vorinostat	2014
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics, 2013, Volume: 8, Issue:9 Topics: Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; M Phase Cell Cycle Checkpoints; Major Histocompatibility Complex; Male; Microarray Analysis; Prostatic Neoplasms; Signal Transduction; Valproic Acid; Vorinostat	2013
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2013, Volume: 27, Issue:10 Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Valproic Acid; Vorinostat	2013
Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood, 2013, Oct-03, Volume: 122, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein; Transfection; Valproic Acid; Vorinostat	2013
HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model. British journal of pharmacology, 2013, Volume: 170, Issue:5 Topics: Acetylation; Analgesics; Animals; Chromatin Assembly and Disassembly; Disease Models, Animal; Epigenesis, Genetic; Ganglia, Spinal; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Hydroxamic Acids; Hypesthesia; Ligation; Male; Mice; Mice, Inbred C57BL; NAV1.8 Voltage-Gated Sodium Channel; Nerve Fibers, Unmyelinated; Pain Measurement; Pain Threshold; Sciatic Nerve; Sciatic Neuropathy; Time Factors; Valproic Acid; Vorinostat	2013
Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human. Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:12 Topics: Acetylation; Animals; Chromatography, Liquid; Gene Expression Regulation; Heart Failure; Heart Transplantation; Heart Ventricles; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lysine; Male; Mice; Myocardial Reperfusion Injury; Myocardium; Proteasome Endopeptidase Complex; Proteolysis; Signal Transduction; Tandem Mass Spectrometry; Valproic Acid; Vorinostat	2013
Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Surgery, 2014, Volume: 155, Issue:2 Topics: Animals; Benzamides; Fibrin; Fibrinogen; Histone Deacetylase Inhibitors; Hydroxamic Acids; Intestines; Intraoperative Care; Male; Peritoneum; Pyridines; Rats; Rats, Wistar; Thromboplastin; Tissue Adhesions; Valproic Acid; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vorinostat; Wound Healing	2014
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. British journal of cancer, 2014, Feb-04, Volume: 110, Issue:3 Topics: Benzamides; Cell Proliferation; Colonic Neoplasms; Flow Cytometry; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Peptides, Cyclic; Proto-Oncogene Proteins c-mdm2; Pyridines; Tumor Suppressor Protein p53; Valproic Acid; Vorinostat	2014
HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer biology & therapy, 2014, Mar-01, Volume: 15, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Necrosis; Neoplastic Stem Cells; Pyrans; Valproic Acid; Vorinostat	2014
Pentyl-4-yn-VPA, a histone deacetylase inhibitor, ameliorates deficits in social behavior and cognition in a rodent model of autism spectrum disorders. European journal of pharmacology, 2014, Mar-15, Volume: 727 Topics: Acetylation; Animals; Behavior, Animal; Cerebellar Cortex; Child Development Disorders, Pervasive; Cognition; Disease Models, Animal; Female; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Male; Maternal Exposure; Maze Learning; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Wistar; Social Behavior; Valproic Acid; Vorinostat	2014
Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide. Free radical biology & medicine, 2014, Volume: 73 Topics: Antioxidants; Cell Hypoxia; Cell Line, Tumor; Cyclic N-Oxides; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Histones; HT29 Cells; Humans; Hydrogen Peroxide; Hydroxamic Acids; Metmyoglobin; Neoplasms; Nitric Oxide; Nitrogen Oxides; Oxidation-Reduction; Oxidative Stress; Radiation-Sensitizing Agents; Spin Labels; Valproic Acid; Vorinostat	2014
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell death & disease, 2014, Oct-02, Volume: 5 Topics: Apoptosis; Cell Cycle Proteins; Cell Death; Cell Survival; Checkpoint Kinase 1; G2 Phase Cell Cycle Checkpoints; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microtubule-Associated Proteins; Mitosis; Nuclear Proteins; Protein Kinases; Rad51 Recombinase; Valproic Acid; Vorinostat	2014
SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells. Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:1 Topics: Antigens, CD34; Basic Helix-Loop-Helix Transcription Factors; Blood Platelets; Cell Differentiation; Cell Lineage; Cells, Cultured; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Megakaryocytes; Plasmids; Protein Interaction Mapping; Proto-Oncogene Proteins; T-Cell Acute Lymphocytic Leukemia Protein 1; Thrombopoiesis; Transcription, Genetic; Valproic Acid; Vorinostat	2015
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Molecular cancer therapeutics, 2015, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; Cell Line, Tumor; Cell Survival; Depsipeptides; DNA Damage; DNA Repair Enzymes; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Fanconi Anemia Complementation Group D2 Protein; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Recombinational DNA Repair; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Valproic Acid; Vorinostat	2015
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis. PloS one, 2015, Volume: 10, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; MCF-7 Cells; Valproic Acid; Vorinostat	2015
Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells. Scientific reports, 2016, Jan-29, Volume: 6 Topics: Acetylation; Amino Acid Motifs; Amino Acid Sequence; Cluster Analysis; Computational Biology; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Lysine; Position-Specific Scoring Matrices; Protein Interaction Mapping; Protein Interaction Maps; Proteome; Proteomics; Valproic Acid; Vorinostat	2016
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget, 2016, Apr-12, Volume: 7, Issue:15 Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Lung Neoplasms; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2016
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. Journal of experimental & clinical cancer research : CR, 2016, 06-17, Volume: 35, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Combined Modality Therapy; Decitabine; Dideoxynucleosides; Epigenesis, Genetic; Humans; Hydroxamic Acids; Medulloblastoma; Mice; Neurogenesis; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Treatment Outcome; Tretinoin; Valproic Acid; Vorinostat; Xenograft Model Antitumor Assays	2016
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. BMC cancer, 2016, 08-22, Volume: 16 Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Melanoma; Neoplasm Invasiveness; rhoA GTP-Binding Protein; RNA Interference; RNA, Small Interfering; Valproic Acid; Vorinostat	2016
Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research. Methods in molecular biology (Clifton, N.J.), 2017, Volume: 1510 Topics: Antigens, CD34; Apoptosis; Biomarkers, Tumor; Cell Culture Techniques; Cell Proliferation; Cell Separation; Cytokines; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Panobinostat; Primary Cell Culture; Signal Transduction; Survivin; Tumor Cells, Cultured; Valproic Acid; Vorinostat	2017
Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons. Biochemical and biophysical research communications, 2017, Jan-22, Volume: 482, Issue:4 Topics: Animals; Calcineurin; Calcium; Calcium-Binding Proteins; Cluster Analysis; Epigenesis, Genetic; Gene Expression Profiling; Green Fluorescent Proteins; Hippocampus; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Neurites; Neurodegenerative Diseases; Neurogenesis; Neurons; Neuroprotective Agents; Oligonucleotide Array Sequence Analysis; Plasmids; Real-Time Polymerase Chain Reaction; Software; Up-Regulation; Valproic Acid; Vorinostat	2017
Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis. Anticancer research, 2017, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Rhabdomyosarcoma; Valproic Acid; Vorinostat	2017
Suberoylanilide hydroxamic acid, a novel histone deacetylase inhibitor, improves the development and acetylation level of miniature porcine handmade cloning embryos. Reproduction in domestic animals = Zuchthygiene, 2017, Volume: 52, Issue:5 Topics: Acetylation; Animals; Cloning, Organism; Embryo Transfer; Embryonic Development; Fertilization in Vitro; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Nuclear Transfer Techniques; Swine; Swine, Miniature; Valproic Acid; Vorinostat	2017
Epigenetic induction of melatonin MT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:8 Topics: Animals; Anticonvulsants; Cell Line, Tumor; Chromatin Immunoprecipitation; CREB-Binding Protein; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epigenesis, Genetic; Glioma; Histones; Hydroxamic Acids; Rats; Receptor, Melatonin, MT1; RNA, Messenger; Signal Transduction; Valproic Acid; Vorinostat	2017
HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors. Journal of dermatological science, 2018, Volume: 90, Issue:1 Topics: Acetylation; Apoptosis; Benzhydryl Compounds; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Hydroxamic Acids; Jurkat Cells; Neoplasms; Pyrrolidinones; Up-Regulation; Valproic Acid; Vorinostat	2018
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2018, Volume: 69 Topics: Antitubercular Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isoniazid; Macrophages; Mycobacterium tuberculosis; Rifampin; THP-1 Cells; Tuberculosis; Valproic Acid; Vorinostat	2018
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clinical epigenetics, 2018, Volume: 10 Topics: B7-H1 Antigen; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Killer Cells, Natural; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; T-Lymphocytes, Regulatory; Valproic Acid; Vorinostat	2018
Effect of valproic acid in comparison with vorinostat on cell growth inhibition and apoptosis induction in the human colon cancer SW48 cells in vitro. Experimental oncology, 2018, Volume: 40, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2018
Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy. Journal of pharmacological sciences, 2018, Volume: 138, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Mice; Neovascularization, Pathologic; Oxygen; Phosphorylation; Retina; Retinal Diseases; Ribosomal Protein S6; Valproic Acid; Vorinostat	2018
Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment. Science China. Life sciences, 2019, Volume: 62, Issue:8 Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Drug Therapy, Combination; Etoposide; Gamma Rays; Histone Deacetylase Inhibitors; Histones; Homeostasis; Humans; Hydroxamic Acids; Methyl Methanesulfonate; Mice; Valproic Acid; Vorinostat	2019
A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis. Pharmacological research, 2019, Volume: 139 Topics: Administration, Oral; Anilides; Animals; Antiprotozoal Agents; Drug Delivery Systems; Female; Gold; Histone Deacetylase Inhibitors; Hydroxamic Acids; Leishmania infantum; Leishmaniasis, Visceral; Mice, Inbred BALB C; Mice, Inbred ICR; Nanoparticles; Valproic Acid; Vorinostat	2019
Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure. BMC ophthalmology, 2019, Feb-04, Volume: 19, Issue:1 Topics: 3-Hydroxybutyric Acid; Antioxidants; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lens, Crystalline; Ultraviolet Rays; Valproic Acid; Vorinostat	2019
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis. Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:1 Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Phagocytosis; Prognosis; Receptor, ErbB-2; Receptors, IgG; Trastuzumab; Valproic Acid; Vorinostat	2020
Epigenetic evidence of an Ac/Dc axis by VPA and SAHA. Clinical epigenetics, 2021, 03-20, Volume: 13, Issue:1 Topics: Acetylation; Cells, Cultured; Epigenesis, Genetic; Epilepsy; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Valproic Acid; Vorinostat	2021
Manipulating histone acetylation leads to antitumor effects in hemangiosarcoma cells. Veterinary and comparative oncology, 2022, Volume: 20, Issue:4 Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Dog Diseases; Dogs; Endothelial Cells; Hemangiosarcoma; Histone Deacetylase Inhibitors; Histones; Valproic Acid; Vorinostat	2022